Evaluation of the impacts of insulin on ovulation in Nigerian women with polycystic ovarian syndrome: a cross-sectional sonographic study

Emmanuel E. Ezugwu, Anthony C. Ugwu, Patrick O. Manafa, Gloria I. Ezugwu


Background: Insulin resistance (IR) is a metabolic state characterized by a decrease in cellular ability to respond to insulin signaling, which contribute to pathophysiological mechanism in the development of all metabolic complication of polycystic ovary syndrome (PCOS). The aim of the study was to match categorized values of patient’s biochemical predisposing factors for polycystic ovaries such as insulin with change in follicular sizes as determined by sonography following CLOMID inducement therapy.

Methods: This experimental study was carried out in Anambra State, Nigeria from June 2018 to May 2021. Those included in the study were women of child bearing age (18 to 45 years) for both groups. The ultrasound examinations and insulin levels measurements were performed on each subject and data such as follicular sizes, insulin levels before and after treatment were recorded. Obtained data were analyzed using both descriptive and inferential statistical tools.

Results: There were no statistically significant mean differences in the insulin levels (t=1.16, p=0.81) and maximal follicular size (t=0.39, p=0.70) of women with and without polycystic ovary who had successful and failed ovulation before the clomid treatment. Both the insulin level (t=2.85, p<0.01) and follicular size (t=4.88, p<0.01) showed statistically significant mean differences. There was significant difference in insulin (F=7.55, p<0.01), with the control having the lowest insulin concentration.

Conclusions: There were statistically significant mean differences in the insulin level and follicular size in women with polycystic ovary after clomid treatment. Therefore, clomiphene citrate inducement triggers increase in serum concentration of insulin.


Follicular, Insulin, Polycystic ovaries

Full Text:



Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370(9588):685–697.

Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-7.

Akpata CB, Uadia PO, Okonofua FE. Prevalence of Polycystic Ovary Syndrome in Nigerian Women with Infertility: A Prospective Study of the Three Assessment Criteria. Open J Obstetr Gynecol. 2018;8:1109-20.

Dewailly, D., Rabin, G., Peigne, M., Decanter, C., Pigny, P., Catteau-jonard, S. Interaction between androgens, FSH, antimullerian hormone and eestradiol during follicullogenesis in the human normal and polycystic ovary. Human Reproduction Update. 2016; 22: 709-724

Saranya. Insulin reference range, interpretation, collection and panels. 2014.

Apridomdze T, Essah PA, Iwrno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metabol. 2005;90(4):L1929-35.

Rojas J, Chavez M, Oliver L, Rojas M, Morillo J, Mejias J et al. Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth. Int J Reproduct Med. 2014;2014:719050.

Ukaji NF, Ohagwu CC, Ogolodom MP. Effects of Variations in Imaging Parameters on Image Quality of Non-Contrast Computed Tomography Scans of Brain: A Cross-sectional Study. JCDR. 2021;15(10):TC13-5.

Ogolodom MP, Ugwu AC, Akosile CO. Pattern of Magnetic Resonance Imaging Findings in Lumbar Spine Pathologies and its Correlation with Demographic variables in Rivers State. J Clin Diagnostic Res. 2021;15(6):TC5-9.

Reaven G. Insulin resistance and compensatory hyperinsulinemia: the linchpin between obesity and cardiovascular disease. J Chair on Cardiometabolic Risk. 2008;1(2):3-10.

Eastham RD. Biochemical values in clinical medicine. 7th ed. England: John Wright and Sons Ltd; 1985.

Sowers MF, Beebe JL, McConne D, Randolph J, Jannausch M. Testosterone concentration in women aged 25-50 years: Association with lifestyles, Body Composition and ovarian status. Am J Epidemiol. 2001;153(3):256-64.

Sander RC, Winter TC. Clinical Sonography: A Practical Guide (Clinical Sonography: A Practical Guide. 4th ed. ‎Philadelphia: Lippincott Williams and Wilkins; 2006.

Ping P, Xiaoli C, Yu L, Qingxue Z, Xiaomiao Z, Madafeitom MA, Bodombossou D, Dongzi Y. Comparison of Manual and Automated Measurements of Monodominant Follicle Diameter with Different Follicle Size in Infertile Patients. PLOS. 2013;8(10):e77095.

Wafa YAES, Labib MM, Fatah AGKAE. Role of Letrozole Versus Clomiphene Citrate in Induction of Ovulation in Patients with Polycystic Ovarian Syndrome. J Gynecol Reproduct Med. 2017;1(1):2-6.

Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Human Reproduction Update. 2009;15(4):477-88.

Zeba D, Biswas R, Fatema K, Khair MA, Zesmin F, Sharifa J. Letrozole or Clomiphene Citrate for Induction of Ovulation in Patients with Polycystic Ovarian Syndrome: A Prospective Randomized Trial. Faridpur Med College J. 2018;13(2):78-81.

Sussan S. Obesity and polycystic ovary syndrome. Obese management. 2007;3(2):69-73.

Al-Azemi M, Omu FE, Omu AE. The effect of obesity on the outcome of infertility management in women with polycystic ovary syndrome. Arch Gynecol Obstetr. 2004;270:205-10.

Hoeger KM. Obesity and lifestyle management in polycystic ovary syndrome. Clin Obstetr Gynecol. 2007;50(1):277-94.

Norman RJ, Davies MJ, Lord J, Norman LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends in Endocrinology and Metabolim. 2002;13(6):251-8.

Norman RJ. Metformin-compsarism with other therapis in ovulation in polycystic ovary syndrome. J Clin Endocrinol Metabol. 2004;89:4797-800.

Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. Brit J Obstetr Gynecol. 2006;113(10):1148-59.

Hoffman B, Schorge J, Schaffer J, Lisa M, Karen D, Gary Cunningham F. Polycystic ovarian syndrome and hyperandrogenism. Williams Gynecology. 2nd ed. New York, NY: McGray-Hill Companies Inc; 2012: 400-606.

Kar S. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: A prospective randomized trial. J Human Reproduct Sci. 2012;5(3):262-5.

Bayar U, Tanriverdi HA, Aykut B, Ayoglu F, Ozcan O, Erdal K. Letrozole vs clomiphene citrate in patients with ovulatory infertility. Fertility Sterility. 2006;85:1045-48.

Zeinalzadeh M, Basirat Z, Esmalpour M. Efficacy of letrozole in ovulation induction compared to that of clomiphene citraye in patients with polycystic ovarian syndrome. J Reproduc Med. 2010;55:36-40.

Wu L, Nicholson W, Knobel SM, Steffner RJ, May JM, Piston DW et al. Oxidative Stress Is a Mediator of Glucose Toxicity in Insulin-secreting Pancreatic Islet Cell Lines. J Biol Chem. 2004;279(13):12126-34.

Baillageon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effect of metformin and rosiglitazone alone and in combination in lean women with plolycystic ovary syndrome and normal indeces of insulin sensitivity. Fertility Sterility. 2004;82:893-902.

Zhu JL, Feng WJ, Long SL, Mo ZC. Sex hormone-binding globulin and polycystic ovary syndrome. Clin Chim Acta. 2019;499:142-8.

Ainehchi N, Khaki A, Ouladsahebmadarek E, Hammadeh M, Farzadi L, Farshbaf-Khalili A et al. The effect of clomiphene citrate, herbal mixture and herbal mixture along with clomiphene citrate on clinical and para-clinical parameters in infertile women with polycystic ovary syndrome: a randomizedcontrolled clinical trial. Arch Med Sci. 2020;16(6):1304-18.

Parsanezhad ME, Alborzi S, Zarei A, Dehbashi S, Omrani G. Insulin resistance in clomiphene responders and nonresponders with polycystic ovarian disease and therapeutic effects of metformin. Int J Gynaecol Obstetr. 2001;75:43-50.